Sotatercept significantly reduces pulmonary vascular resistance and mean pulmonary artery pressure, improving right ventricular-pulmonary artery (RV-PA) coupling in patients with pulmonary arterial hypertension (PAH).
Systemic decongestion by sotatercept leads to hemoconcentration, elevating hemoglobin concentration without increasing red cell mass, thereby enhancing oxygen transport capacity.
Despite a reduction in resting cardiac output (CO), sotatercept increases CO reserve during exercise, which correlates strongly with improved peak oxygen consumption and aerobic capacity.
Skeletal muscle oxygen delivery and utilization are enhanced after sotatercept treatment, contributing to improved peripheral oxygen extraction and single-leg exercise performance.
